BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
Phase 1
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT01184820
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
Phase 2
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT01179334
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom
🇨🇿Vseobecna fakultni nemocnice, Praha 2, Czech Republic
Japanese BAY86-9766 Monotherapy Phase I Study
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01179295
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
Phase 2
Terminated
- Conditions
- Ventricular Dysfunction, LeftHypertension, Pulmonary
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT01172756
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
Phase 1
Completed
- Conditions
- InfectionPulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01168895
Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors
Phase 2
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 140
- Registration Number
- NCT01168817
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3310
- Registration Number
- NCT01167231
Coronary Vasomotor Response After Riociguat Exposure
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Bayer
- Registration Number
- NCT01165931
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Completed
- Conditions
- Lymphoma, FollicularNon-Hodgkin Lymphoma
- Interventions
- Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT01164696
A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment
Phase 3
Completed
- Conditions
- Age-Related Memory Disorders
- Interventions
- Dietary Supplement: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)Other: Placebo
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2010-08-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 132
- Registration Number
- NCT01160692